Mapi Pharma Ltd., of Ness Ziona, Israel, completed an equity investment of $10 million by Zhejiang Jingxin Pharmaceutical Co. Ltd., of Xinchang, China. Jingxin is also a current shareholder of Mapi, following an initial $10 million investment in 2016. The funds raised will support Mapi’s future development and enable the expansion of the company pipeline, officials said.